EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

Chaparro, M. ; Barreiro-de Acosta, M. ; Benítez, J.M. ; Cabriada, J.L. ; Casanova, M.J. ; Ceballos, D. ; Esteve, M. ; Fernández, H. ; Ginard, D. ; Gomollón, F. (Universidad de Zaragoza) ; Lorente, R. ; Nos, P. ; Riestra, S. ; Rivero, M. ; Robledo, P. ; Rodríguez, C. ; Sicilia, B. ; Torrella, E. ; Garre, A. ; García-Esquinas, E. ; Rodríguez-Artalejo, F. ; Gisbert, J.P. ; Alfambra, E.

Resumen: Background: Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes. Methods: This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded. Results: The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up. Conclusions: The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD.

Idioma: Inglés

DOI: 10.1177/1756284819847034

Año: 2019

Publicado en: Therapeutic Advances in Gastroenterology 12 (2019), 1-11
ISSN: 1753-283X

Factor impacto JCR: 3.52 (2019)

Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 40 / 88 = 0.455 (2019) - Q2 - T2

Factor impacto SCIMAGO: 1.29 - Gastroenterology (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI16-01296
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI17-00143

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)